Scott M Lippman

发表

Algorithmic Guided Screening of Drug Combinations of Arbitrary Size for Activity against Cancer Cells

Li Mao, Paul Damien, Elmira Popova, 2022 .

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Norman Wolmark, Scott M Lippman, S. Reis, 2006, JAMA.

Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer.

Jian Gu, Yuanqing Ye, Scott M Lippman, 2013, Cancer research.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Michael Peyton, Li Shen, John N Weinstein, 2012, Cancer discovery.

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

Ian M Thompson, Lori M Minasian, Scott M Lippman, 2014, Journal of the National Cancer Institute.

Transforming Cancer Prevention through Precision Medicine and Immune-oncology

Avrum Spira, J Jack Lee, Zigang Dong, 2016, Cancer Prevention Research.

Positive Surgical Margins in the 10 Most Common Solid Cancers

Ryan K. Orosco, Anne Wallace, Karen Messer, 2018, Scientific Reports.

Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.

Jian Gu, Joe Y. Chang, Yuanqing Ye, 2011, Journal of the National Cancer Institute.

Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events.

Dong Soon Choi, Scott M Lippman, S. Lippman, 2011, Blood.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Quynh-Thu Le, Martin G Pomper, Levi Garraway, 2017, The Lancet. Oncology.

Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large-Scale Evaluation of Genetic Variants

Jian Gu, J Jack Lee, Yuanqing Ye, 2009, Cancer Prevention Research.

Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.

Jacqueline Kerr, Scott M Lippman, S. Lippman, 2017, The Lancet. Oncology.

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

Scott M Lippman, S. Lippman, A. El‐Naggar, 2012, Expert opinion on therapeutic targets.

Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss

Ryan K. Orosco, Trey Ideker, Hannah Carter, 2014, Nature Genetics.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

John V Heymach, Kevin R Coombes, Lixia Diao, 2012, Journal of the National Cancer Institute.

The influence of finasteride on the development of prostate cancer.

Michael M Lieber, Ian M Thompson, Scott M Lippman, 2003, The New England journal of medicine.

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize

Karra A. Jones, Karra A Jones, Scott M Lippman, 2016, Nature Communications.

Science peels the onion of selenium effects on prostate carcinogenesis.

Scott M Lippman, H. Parnes, S. Lippman, 2004, Journal of the National Cancer Institute.

Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.

Trey Ideker, Hannah Carter, Christopher M. DeBoever, 2017, Cancer discovery.

Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions.

J Jack Lee, Scott M Lippman, Xifeng Wu, 2008, European journal of cancer.

Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.

Robert A Newman, Gabriela Mendoza, David G Menter, 2005, Cancer research.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Scott M Lippman, Jean-Yves Douillard, 2008, The Lancet.

Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers.

Joe Y. Chang, V Shane Pankratz, Yuanqing Ye, 2013, Cancer research.

Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer.

Mi-Kyoung Kim, B Nebiyou Bekele, Scott M Lippman, 2008, Cancer research.

CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

John V Heymach, Young-Ho Ahn, Roy S Herbst, 2013, Cancer research.

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Michael M Lieber, J Michael Gaziano, Ian M Thompson, 2005, Journal of the National Cancer Institute.